PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Shekhar, A.* ; Di Lucrezia, R.* ; Jerye, K.* ; Korotkov, V.S.* ; Harmrolfs, K.* ; Rox, K.* ; Weich, H.A.* ; Ghai, I.* ; Delhommel, F. ; Becher, I.* ; Degenhart, C.* ; Fansa, E.* ; Unger, A.* ; Habenberger, P.* ; Klebl, B.* ; Lukat, P.* ; Schmelz, S.* ; Henke, S.* ; Borgert, S.* ; Lang, J.C.* ; Sasse, F.* ; Diestel, R.* ; Richter, C.* ; Schneider-Daum, N.* ; Hinkelmann, B.* ; Niemz, J.* ; Lehr, C.M.* ; Jänsch, L.* ; Huehn, J.* ; Alm, R.* ; Savitski, M.M.* ; Welte, T.* ; Hesterkamp, T.* ; Sattler, M. ; Winterhalter, M.* ; Blankenfeldt, W.* ; Medina, E.* ; Bilitewski, U.* ; Dinkel, K.* ; Brönstrup, M.*

Highly potent quinoxalinediones inhibit α-hemolysin and ameliorate Staphylococcus aureus lung infections.

Cell Host Microbe 33, 560-572.e21 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Hospital-acquired pneumonia caused by Staphylococcus aureus is associated with patient morbidity and mortality, despite adequate antibiotic therapy. This illustrates the need for treatments beyond antibiotics. The pore-forming heptameric toxin α-hemolysin (Hla) is a major pathogenicity factor of S. aureus and a clinically validated target. We identify quinoxalinediones (QDS) as highly potent Hla inhibitors, conferring protection against the hallmarks of Hla-induced pathogenicity such as Ca2+ influx, cytotoxicity, hemolysis, and monolayer destruction. The effects were exerted across major Hla subtypes in all relevant cell types. QDS prevented the formation of functional pores by interacting with Hla near the phospholipid-binding site. The QDS analog, H052, was active in mouse models of S. aureus lung infections, when administered prophylactically or therapeutically, either as monotherapy or when given in combination with the antibiotic linezolid. The study provides evidence that complex bacterial toxins can be targeted in vivo by drug-like small molecules.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
18.700
0.000
1
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Staphylococcus Aureus ; Antibacterials ; Drug Discovery ; Lung Infections ; Mechanism Of Action ; Toxin Inhibition ; Virulence Inhibitors; Alpha-hemolysin; Monoclonal-antibody; Escherichia-coli; Nmr-spectroscopy; Pneumonia; Toxin; Expression; Virulence; Prevention; Strategies
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 1931-3128
e-ISSN 1934-6069
Zeitschrift Cell Host & Microbe
Quellenangaben Band: 33, Heft: 4, Seiten: 560-572.e21 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Structural Biology (STB)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-503000-001
Förderungen
Drug Discovery and Cheminformatics for New Anti-Infectives" (iCA)
German Center for Infection Research
HZI pre-4D fund
Helmholtz Validation Fund
DOI 10.1016/j.chom.2025.03.006
WOS ID 001468017200001
Scopus ID 105001497320
Scopus ID 105001681958
PubMed ID 40168998
Erfassungsdatum 2025-05-09
[➜Korrektur melden]